No Data
No Data
Dabo Healthcare (002901.SZ): 2023 net profit of 589.725 million yuan, a year-on-year decrease of 36.28%
Gelonghui, March 29丨Dabo Healthcare (002901.SZ) released its 2023 annual report. In 2023, the company achieved operating income of 1,533 billion yuan, an increase of 6.90%; net profit attributable to shareholders of listed companies was 589.725 million yuan, a year-on-year decrease of 36.28%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 10.551 million yuan, a year-on-year decrease of 88.45%; basic earnings per share were 0.14 yuan
Dabo Medical (002901.SZ): Currently, there is no application of medical information+AI medicine in product development
Gelonghui March 20 丨 An investor asked Dabo Healthcare (002901.SZ) on the investor interactive platform, “The company is a leading orthopedic enterprise. Does the company currently have any product development aspects, apply medical information+AI medicine?” The company replied that the company currently does not apply medical information+AI medicine in product development.
Dabo Healthcare (002901): The impact of collection is gradually being clarified. Focus on marginal changes in the company's operations
The performance was in line with expectations. The impact of collection was gradually cleared in the first three quarters of 2023. The company achieved revenue of 1,125 billion yuan, a year-on-year decrease of 8.86%; net profit to mother was 98 million yuan, a year-on-year decrease of 54.03%. In the third quarter,
Dabo International, the majority shareholder of Dabo Medical (002901.SZ), reduced its holdings by a total of 2.21%, and the stock reduction period expired
Dabo Healthcare (002901.SZ) issued an announcement. As of the disclosure date of this announcement, Dabo International's current holdings reduction plan is for...
Guojin Securities: Announcement of the results of the fourth batch of consumables proposed for domestic procurement, optimistic about the continued release of artificial crystal products
It is expected that the products of domestic listed artificial crystals will continue to be released, and domestic replacement of bifocal artificial crystals will begin.
Guotai Junan: Moderate election rules and national adoption are expected to accelerate the number of domestic companies admitted to hospital
Guotai Junan released a research report saying that the localization rate of sports medicine has increased dramatically, and Guotai Junan is expected to accelerate the number of domestic companies admitted to hospital.
No Data